Literature DB >> 17768138

Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients.

F Forghieri1, M Luppi, M Morselli, L Potenza.   

Abstract

Potentially fatal lung toxicity occurs in 12-20% of leukemic patients treated with cytarabine especially at intermediate to high doses, usually presenting as noncardiogenic pulmonary edema (NCPE). Anecdotally the association between cytarabine and the onset of bronchiolitis obliterans organizing pneumonia (BOOP) has been reported. We describe here three cases of patients affected by acute myeloid leukemia (AML) treated with chemotherapeutic regimens including high dose cytarabine, who developed early onset of fever, mild dyspnea, moderate hypoxemia on arterial blood gas analysis and lung infiltrates documented by high-resolution computerized tomography (HRCT), with a more indolent behaviour and a benign clinical outcome, compared with similar cases previously reported in the literature. Our cases widen the spectrum of clinical features of cytarabine-related toxicity in leukemic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768138     DOI: 10.3324/haematol.11697

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  3 in total

1.  Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study.

Authors:  Daniel Shepshelovich; Yonatan Edel; Hadar Goldvaser; Tal Dujovny; Ofir Wolach; Pia Raanani
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

2.  Hematologic neoplasms: interpreting lung findings in chest computed tomography.

Authors:  P Calvillo Batllés; J Carreres Polo; J Sanz Caballer; M Salavert Lletí; L Compte Torrero
Journal:  Radiologia       Date:  2015-08-24

3.  Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia.

Authors:  Ajay Abraham; Anup J Devasia; Savitha Varatharajan; Sreeja Karathedath; Poonkuzhali Balasubramanian; Vikram Mathews
Journal:  Ann Hematol       Date:  2014-11-13       Impact factor: 3.673

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.